Alfa Institute of Biomedical Sciences and the Department of Medicine−Infectious Diseases, Iaso General Hospital, Athens, Greece; the Department of Medicine, Karolinska Institutet and University Hospital, Stockholm, and the Department of Pediatrics, Central Hospital, Karlstad, Sweden; and the Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts.
Corresponding author: Matthew Ε. Falagas, MD, MSc, Alfa Institute of Biomedical Sciences (AIBS), 9 Neapoleos Street, 151 23 Marousi, Athens, Greece; e-mail: [email protected].
Konstantinos A. Polyzos was supported by the Alexander Onassis Public Benefit Foundation.
Financial Disclosure Dr. Falagas has participated in the advisory boards of Achaogen, Astellas, AstraZeneca, Bayer, and Pfizer; has received lecture honoraria from Angelini, Astellas, AstraZeneca, Glenmark, Merck, and Novartis; and has received research support from Angelini, Astellas, and Rokitan. The other authors did not report any potential conflicts of interest.
The authors thank Dr. Källén and Dr. Schaefer for providing additional information on their studies.